Expand VNDA Menu
VNDA MENU

VNDA Latest Press Releases

-- May 7, 2026 --

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences PRNewswire 6:44 PM

-- May 1, 2026 --

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years PRNewswire 4:36 PM

-- April 29, 2026 --

Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 PRNewswire 4:30 PM

-- April 28, 2026 --

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence PRNewswire 7:13 PM

-- April 22, 2026 --

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors PRNewswire 5:14 PM

-- April 9, 2026 --

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines PRNewswire 11:03 AM

-- April 8, 2026 --

Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists PRNewswire 4:56 PM

-- March 19, 2026 --

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods PRNewswire 4:35 PM

-- March 3, 2026 --

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years PRNewswire 8:02 AM

-- February 26, 2026 --

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference PRNewswire 4:35 PM

-- February 25, 2026 --

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis PRNewswire 7:18 AM

-- February 20, 2026 --

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation PRNewswire 5:59 PM

-- February 12, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PRNewswire 6:56 PM

-- February 11, 2026 --

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results PRNewswire 4:01 PM

-- February 4, 2026 --

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 PRNewswire 6:02 PM

-- February 3, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA Globe Newswire 1:40 PM

-- January 29, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PRNewswire 10:00 AM

-- January 22, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PRNewswire 10:00 AM

-- January 20, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA Globe Newswire 1:11 PM

-- January 15, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PRNewswire 10:00 AM

-- January 13, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA Globe Newswire 3:49 PM

-- January 8, 2026 --

Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder PRNewswire 7:00 AM

-- December 30, 2025 --

Vanda Pharmaceuticals Announces FDA Approval of NEREUS (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness PRNewswire 6:13 PM
Market Data Delayed 15 Minutes